Ruzasvir clinical trials
Also written MK-8408.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses ruzasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Merck Sharp & Dohme LLC (5) · Atea Pharmaceuticals, Inc. (2)
Often tested with
Tested in the same studies.
Uprifosbuvir (4) · Bemnifosbuvir (2) · AT-511 (1) · Grazoprevir (1) · Elbasvir (1) · MK-3682B (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses ruzasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)CompletedPhase 1Atea Pharmaceuticals, Inc.NCT07272889Written as Bemnifosbuvir/Ruzasvir (BEM/RZR)
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVCompletedPhase 2Atea Pharmaceuticals, Inc.NCT05904470Written as Ruzasvir
- Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02956629Written as Ruzasvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Ruzasvir
- Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02759315Written as Ruzasvir 60 mg
- Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT02076100Written as Ruzasvir
- A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)CompletedPhase 1Merck Sharp & Dohme LLCNCT02666352Written as Ruzasvir
Given beside what is tested · 1 — ruzasvir is usual care or a partner of the new treatment
Codes
What other systems call ruzasvir · ClinicalTrials.gg INT000748
- MeSH (NLM) C000621654ruzasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LX752BD95YRUZASVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27283234ruzasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152277RuzasvirOne source FDA
- DrugBank DB11713One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621654 | ruzasvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LX752BD95Y | RUZASVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27283234 | ruzasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152277 | Ruzasvir | One source FDA |
| DrugBank | DB11713 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.